Domain‐specific cognitive impairment in non‐demented Parkinson's disease psychosis

Abstract

Introduction In Parkinson's disease (PD), psychosis is associated with cognitive impairment that may be more profound in particular cognitive domains. Our goal was to determine whether psychosis in non‐demented PD participants is associated with domain‐specific cognitive impairment on the Mini‐Mental State Exam (MMSE). Methods The Morris K. Udall Parkinson's Disease Research Center of Excellence Longitudinal Study at Johns Hopkins is a prospective study that was initiated in 1998. Clinical assessments are conducted at two‐year intervals at the Johns Hopkins Hospital. We analyzed data from 137 enrolled participants with idiopathic PD. Psychosis diagnoses were established by psychiatrist interview per DSM‐IV criteria. An incident dementia diagnosis resulted in exclusion from analysis for that evaluation and any future evaluations in that participant. We used logistic regression with generalized estimated equations (GEE) to model the time‐varying relationship between MMSE subscale scores and psychosis, adjusting for potential confounding variables identified through univariable analysis. Results Thirty‐one unique psychosis cases were recorded among non‐demented participants. Fifty total evaluations with psychosis present were analyzed. In multivariable regressions, psychosis was associated with lower scores on the orientation (relative odds ratio, rOR: 0.73; 95% CI: 0.58–0.93; p = 0.011), language (rOR: 0.64; 95% CI: 0.48–0.86; p = 0.003), and intersecting pentagon (rOR: 0.43; 95% CI: 0.20–0.92 p = 0.030) subscales of the MMSE. Conclusions In PD, executive dysfunction, disorientation, and impaired language comprehension may be associated with psychosis. Our findings suggest that the corresponding MMSE subscales may be useful in identifying participants with a higher likelihood of developing psychosis. Copyright © 2017 John Wiley & Sons, Ltd.

Adherence to High Dietary Diversity and Incident Cognitive Impairment for the Oldest-Old: A Community-Based, Nationwide Cohort Study

“…Notably, the different cognitive domains in the current study were calculated based on the MMSE items. The method has been used in previous studies [ 30 ], and the MMSE domain-specific cognitive impairment aligns with the performance in detailed neuropsychological tests, which might be useful to guide further neuropsychological tests [ 60 , 61 ]. It can be considered as a proxy since the assessments of domain-specific cognitive function in our study were unavailable.…”

Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline

“…This predictive relationship between cognitive decline and real-world functioning is not unique to Alzheimer's disease (AD). Cognitive impairment is now recognized as a core or common feature and source of functional impairment in an etiologically diverse set central nervous system (CNS) disorders, including multiple sclerosis (MS) (6-8), Parkinson's disease (9)(10)(11)(12), schizophrenia (13)(14)(15)(16)(17)(18), major depression (19) and bipolar disorder (20-22), among others. In MS, for instance, impairments in processing speed and executive functioning are common early symptoms associated with disease progression and relapse, the onset of which may precede clinical manifestation of motor symptoms (6)(7)(8).…”

“…In MS, for instance, impairments in processing speed and executive functioning are common early symptoms associated with disease progression and relapse, the onset of which may precede clinical manifestation of motor symptoms (6)(7)(8). In Parkinson's disease, subjective and subtle objective cognitive impairment has been shown to predict diagnosis by up to 9 years, and cognitive decline is now recognized within the emerging research framework for prodromal disease (9)(10)(11)(12)23). In symptomatic PD, as in other neurodegenerative diseases, cognitive impairment is associated with reductions in functional independence and with increases medical costs, caregiver burden and mortality (24).…”

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications

“…In addition to psychosis, cognitive impairment, including dementia, is another common and disabling nonmotor symptom in PD . Numerous studies have reported a strong association between cognitive impairment and PDP . Thus, it is important that an antipsychotic used to treat PDP be effective, well tolerated, and safe across the cognitive spectrum and when used in combination with cognitive‐enhancing medications.…”